Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DASSOH trial of systematic desmopressin to prevent sodium overcorrection in severe hyponatremia
2023-507254-32-00Phase 3Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2024
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of desmopressin in hyponatraemia (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Proportion of patients with serum sodium overcorrection within 48 hours and Definition of serum sodium overcorrection. Planned start May 2024; status: authorised.
02
Drugs
desmopressin
03
Conditions
hyponatraemia
Beyond the preview
Go deeper on 2023-507254-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507254-32-00.